NCT00048139View on ClinicalTrials.gov

A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Colorectal Cancer
Interventions
DRUG

Irinotecan

250mg/m2 iv on day 1 of each 3 week cycle

DRUG

capecitabine [Xeloda]

1000mg/m2 po bid on days 1-15 of each 3 week cycle

Trial Locations (11)

14263

Buffalo

67502

Hutchinson

77030

Houston

80262

Denver

85012

Phoenix

87102

Albuquerque

89109

Las Vegas

92708

Fountain Valley

95403

Santa Rosa

92037-1030

La Jolla

87131-5636

Albuquerque

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00048139 - A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter